本文選題：呋喃唑酮 + 幽門螺桿菌　； 參考：《廣西醫(yī)科大學(xué)》2015年碩士論文

【摘要】：目的：評價與常規(guī)四聯(lián)療法相比,含呋喃唑酮的四聯(lián)療法補救根除幽門螺桿菌的療效及安全性。方法：計算機(jī)檢索中國知網(wǎng)、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫、維普中文科技期刊數(shù)據(jù)庫、Pubmed、EMBASE、Cochrane,納入含呋喃唑酮的四聯(lián)療法與常規(guī)四聯(lián)療法對比,補救根除Hp的隨機(jī)對照試驗。采用RevMan5.0軟件進(jìn)行Meta分析,治療結(jié)局(Hp根除率、不良反應(yīng)發(fā)生率)用比值比(Odds ratio, OR)為評價指標(biāo),并計算95%可信區(qū)間(95%CI)。納入研究間的異質(zhì)性采用x 2檢驗。結(jié)果：納入6個研究,共788例患者,含呋喃唑酮的治療組396例,常規(guī)療法的對照組392例。Meta分析顯示,含呋喃唑酮的四聯(lián)療法與常規(guī)四聯(lián)療法對比,補救根除Hp的根除率更高,按ITT分析時P=0.05,OR=1.83,95% CI (1.00,3.42),按PP分析時P=0.004,0R=1.99,95%CI(1.25,3.17),兩組不良反應(yīng)發(fā)生率無統(tǒng)計學(xué)意義(P0.05)。結(jié)論：與常規(guī)四聯(lián)療法相比,含呋喃唑酮的四聯(lián)療法補救根除Hp的療效更好,不良反應(yīng)的發(fā)生率無明顯差異。
[Abstract]:Objective: to evaluate the efficacy and safety of furazolidone combined therapy for the eradication of Helicobacter pylori.Methods: a computer search was conducted to search the database of Chinese Biomedical Literature, Chinese Journal of Science and Technology, Pubmedmeda EMBASE Cochrane.Compared with the conventional tetralogy of furazolidone, a randomized controlled trial was conducted to remedy the eradication of HP.RevMan5.0 software was used for Meta analysis. The rate of HP eradication and the incidence of adverse reactions were analyzed by RevMan5.0 software. The ratio ratio of odds ratios (ORs) was used as the evaluation index, and 95% confidence interval (95% CI) was calculated.The heterogeneity between the inclusion studies was tested by x 2 test.Results: a total of 788 patients, 396 patients with furazolidone, and 392 patients with conventional therapy (control group) were enrolled in 6 studies. Meta analysis showed that the eradication rate of HP was higher in the quadruple therapy containing furazolidone than in the conventional tetralogy.According to ITT analysis, 1.83 95% CI 1.00 and 3.42% CI, respectively, according to PP analysis, the incidence of adverse reactions in the two groups was not statistically significant (P 0.05), and the incidence of adverse reactions in the two groups was not statistically significant (P < 0.05). The incidence of adverse reactions in the two groups was not significantly higher than that in the control group (P < 0.05), and the incidence of adverse reactions was not significant in the two groups (P < 0.05).Conclusion: compared with conventional tetralogy, the treatment with furazolidone has a better curative effect on HP eradication, and there is no significant difference in the incidence of adverse reactions.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R573

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 汪平凡;高虎云;楊新葉;范勇;;呋喃唑酮不良反應(yīng)(附藥疹祖孫三代一家系報告)[J];臨床醫(yī)學(xué);2008年10期

2 劉元;周洲;;阿莫西林聯(lián)合呋喃唑酮四聯(lián)復(fù)治幽門螺桿菌的療效觀察[J];中外醫(yī)療;2013年34期

3 呂清;朱凌音;陸紅;;含左氧氟沙星的四聯(lián)療法與常規(guī)四聯(lián)療法補救治療幽門螺桿菌感染療效的Meta分析[J];實用藥物與臨床;2013年12期

4 溫晉鋒;王伯軍;丁勇;郭利華;胡桂梅;葉國良;;含多西環(huán)素的四聯(lián)方案根除幽門螺桿菌的療效[J];中國臨床保健雜志;2014年03期

5 李丙生;甘愛華;許岸高;王新穎;張曉慧;余中貴;;莫西沙星、埃索拉唑和呋喃唑酮三聯(lián)根除幽門螺桿菌的療效觀察[J];中國感染與化療雜志;2014年04期

6 黎莉;楊衛(wèi)文;楊景林;;幽門螺桿菌感染與胃腸外疾病的關(guān)系[J];河北聯(lián)合大學(xué)學(xué)報(醫(yī)學(xué)版);2013年02期

7 尤麗財;彭孝緯;;幽門螺桿菌對呋喃唑酮的耐藥狀況及耐藥機(jī)制的研究[J];胃腸病學(xué)和肝病學(xué)雜志;2009年05期

8 張萬岱;胡伏蓮;蕭樹東;徐智民;;中國自然人群幽門螺桿菌感染的流行病學(xué)調(diào)查[J];現(xiàn)代消化及介入診療;2010年05期

9 陳云華;汪春蓮;謝云;;幽門螺桿菌致病機(jī)制及益生菌防治作用的研究進(jìn)展[J];世界華人消化雜志;2007年25期

10 ;Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai[J];World Journal of Gastroenterology;2010年40期

，

本文編號：1771164